From a therapeutic standpoint, targeting the JAK/STAT pathway with Janus kinase inhibitors, already used in the treatment of rheumatoid arthritis and certain cancers, offers a promising strategy to reduce the inflammatory and apoptotic effects of MGO in various diseases [220,221,222]. Here, SOAT1 is linked to cancer.